Aug 2026· Journal of Chemical Information and Modeling· 0 citations· 47 references
TL;DR
Results indicate that FragSyn, through the synergistic design of fragment-level representation and cellular context awareness, provides an effective and interpretable new approach to synergistic drug combination prediction.
Abstract
Drug combination therapy plays an increasingly important role in the clinical treatment of complex diseases, such as cancer, as rational drug combinations can enhance therapeutic efficacy and reduce toxic side effects. However, existing methods still exhibit limitations in the granularity of drug molecular representation, drug interaction modeling, and cell line context awareness, which restrict further improvements in predictive performance. To address these issues, we propose FragSyn, a deep graph learning framework for predicting synergistic drug combinations based on molecular fragmentations. FragSyn first decomposes drug molecules into chemically meaningful fragments according to breaks of retrosynthetically interesting chemical substructure rules and learns fragment-level molecular representations through a graph isomorphism network with edge features. It then captures nonlinear relationships between drug pairs from multiple perspectives while introducing a gating modulation mechanism conditioned on cell line features, enabling drug representations to adapt dynamically to the cell line context. Finally, multisource features are fused to perform binary classification of synergy versus antagonism. FragSyn achieves AUC, AUPR, and ACC of 0.944, 0.942, and 0.872, respectively, outperforming eight baseline models, and demonstrates optimal generalization performance in both leave-one-out cross-validation and external validation. Ablation studies and interpretability analyses further validate the rationality of FragSyn and its ability to identify key fragments. These results indicate that FragSyn, through the synergistic design of fragment-level representation and cellular context awareness, provides an effective and interpretable new approach to synergistic drug combination prediction.
The DRL-DSP is proposed, a novel dual representation learning framework designed to enhance drug synergy prediction by integrating molecular-level features from SMILES sequences with graph-level relational information from reconstructed molecular networks.
Juanzi Zhou, Xiaoliang Yang, Yin Zhang et al.· Intelligent Data Analysis· 0 citations
MKASynergy, an adaptive drug synergy prediction method based on a mixture-of-experts kernel mechanism, achieves competitive predictive performance and visualization analysis confirms the model’s effectiveness in feature decoupling and helps interpret latent drug synergistic mechanisms.
Cundong Lin, Jiancheng Ni, Ying Yang et al.· Network Modeling Analysis in...· 0 citations
A novel multiview feature fusion-based graph representation model (MFF-GRM) for predicting DDI that integrates drug molecular graphs, SMILES sequences, DDI information networks, and drug biological features to learn drug features more comprehensively.
Mengyuan Jin, Dan Liu, E. Benfenati et al.· Applied intelligence (Boston...· 0 citations
An innovative dual-branch approach based on Graph Isomorphism Network drug representations coupled with a Multilayer Perceptron (MLP) for 50-dimensional ssGSEA pathway activities calculated from CCLE gene expression is proposed, proving the importance of biological features in the two-branch model.
With the increasing use of multiple medications in clinical practice, accurate and interpretable prediction of organ-level adverse drug reactions (ADRs) induced by drug combinations is essential for drug safety assessment and precision medicine. Existing knowledge graph (KG)-based methods primarily model biomedical associations but leave direct structure-level interactions within drug pairs undercharacterized, while molecular representation methods often rely on whole-molecule or latent substructure encodings, offering limited chemically meaningful evidence for ADR risks. This study proposes MolADR, a multiscale complementary learning framework that integrates GNN-based KG learning with dual-granularity molecular cross-attention modeling to combine macro-level biomedical associations with microlevel molecular interaction cues. Under an emerging-drug setting, MolADR achieves PR-AUC scores of 81.17 ± 3.97, 84.04 ± 4.67, and 74.37 ± 9.90 on three data sets, consistently outperforming state-of-the-art baselines, with further analyses supporting its robustness and suggesting its ability to highlight chemically plausible atoms and functional groups for organ-level ADR prediction.
Yifan Qi, Q. Ren, Chen-Xu Wang et al.· Journal of Chemical Informat...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.